DURANCE is a two part, phase Ib/II, multi-centre study to assess the safety and activity of S-488210/S-488211 in combination with durvalumab, in patients with non-muscle invasive bladder cancer (NMIBC).
Histologically proven high risk non-muscle invasive bladder cancer (NMIBC)
Adequate archival tissue sample available for histological assessment (date sample taken must be within 6 months of planned start of treatment)
Predominant histologic component (> 50%) must be urothelial (transitional cell) carcinoma
Bacillus Calmette-Guerin (BCG) unresponsive disease or are intolerant of BCG therapy
Inflammatory bowel disease (e.g. colitis or Crohn's disease)
Diverticulitis (with the exception of diverticulosis)
Systemic lupus erythematous (SLE)
Sarcoidosis syndrome